Skip to main content
. 2023 Apr 20;36:100768. doi: 10.1016/j.lanwpc.2023.100768

Fig. 3.

Fig. 3

Additional cervical cancer deaths from delaying large-scale vaccination and screening program compared with no-delay scenario (vaccination initiated in 2022 and HPV 2030 screening scenario). (a) Domestic 2vHPV; (b) imported 2vHPV; (c) 4vHPV; and (d) 9vHPV vaccines. Error bars represent the 80% uncertainty intervals of additional deaths. The dark and light blue bars indicate the additional cervical cancer deaths of scenarios with large-scale vaccination initiated in 2022 and 2030, respectively. “HPV 2030”, “HPV 2050”, and “HPV 2070” screening scenarios represent switching to HPV-based screening at 5-year intervals in 2022, with linearly increasing age-specific uptake from status quo in 2021, to 70% in 2030 (rapid), 2050 (moderate), and 2070 (gradual), respectively, followed by a 1% increase every year till 90% is reached. “LBC 2030”, “LBC 2050”, and “LBC 2070” screening scenarios represent maintaining LBC-based screening at 3-year intervals, with the corresponding rapid, moderate, and gradual increase in age-specific uptake. HPV, human papillomavirus; LBC, liquid-based cytology.